Alphatec (ATEC) Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATEC shares.
View ATEC analyst ratings or view top-rated stocks.

6 brokerages have issued 12-month target prices for Alphatec's stock. Their ATEC share price forecasts range from $9.50 to $20.00. On average, they predict the company's share price to reach $16.25 in the next year. This suggests a possible upside of 5.8% from the stock's current price.
View analysts price targets for ATEC or view top-rated stocks among Wall Street analysts.

Alphatec's stock was trading at $12.35 on January 1st, 2023. Since then, ATEC shares have increased by 24.4% and is now trading at $15.36.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ATEC earnings forecast.

Alphatec Holdings, Inc. (NASDAQ:ATEC) posted its quarterly earnings data on Thursday, November, 4th. The medical technology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.20. The medical technology company had revenue of $62.88 million for the quarter, compared to the consensus estimate of $61.43 million. Alphatec had a negative trailing twelve-month return on equity of 575.45% and a negative net margin of 39.28%. During the same period in the previous year, the company posted ($0.18) EPS.

ETFs with the largest weight of Alphatec (NASDAQ:ATEC) stock in their portfolio include Jacob Forward ETF (JFWD), Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Health Care Equipment ETF (XHE), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), Global X Aging Population ETF (AGNG) and iShares Micro-Cap ETF (IWC).

Alphatec issued an update on its first quarter 2023 earnings guidance on Wednesday, April, 19th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $108.00 million-$109.50 million, compared to the consensus revenue estimate of $101.59 million.

19 employees have rated Alphatec Chief Executive Officer Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among the company's employees. 63.0% of employees surveyed would recommend working at Alphatec to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alphatec investors own include Macrocure Ltd. - Ordinary Share (MCUR), LinnCo (LNCOQ), California Resources (CRC), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), (GBSN) (GBSN), Idera Pharmaceuticals (IDRA), Athersys (ATHX), Anavex Life Sciences (AVXL) and BioCryst Pharmaceuticals (BCRX).

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

Alphatec's stock is owned by a variety of institutional and retail investors. Top institutional investors include First Light Asset Management LLC (2.48%), Next Century Growth Investors LLC (1.78%), State Street Corp (1.62%), Cerity Partners LLC (1.57%), JPMorgan Chase & Co. (1.53%) and Geode Capital Management LLC (1.23%). Insiders that own company stock include Craig E Hunsaker, David H Mowry, David R Pelizzon, David Sponsel, Elizabeth Ann Altman, Evan Bakst, James L L Tullis, James L L Tullis, Jason Hochberg, Jeffrey G Black, Jennifer N Pritzker, Jennifer N Pritzker, John Todd Koning, L-5 Healthcare Partners, Llc, Mortimer Berkowitz III, Patrick Miles, Paul Segal and Scott Lish.
View institutional ownership trends.

Shares of ATEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATEC stock can currently be purchased for approximately $15.36.

Alphatec (NASDAQ:ATEC) has a market capitalization of $1.82 billion and generates $350.87 million in revenue each year. The medical technology company earns $-152,150,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

The company employs 561 workers across the globe.

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The official website for the company is www.atecspine.com. The medical technology company can be reached via phone at (760) 431-9286, via email at ir@alphatecspine.com, or via fax at 800-922-1356.